Michael J. Mastrangelo, MD
Professor
Contact
Michael J. Mastrangelo, MD
Professor
Education
Medical School
Johns Hopkins University School of Medicine - 1964
Residency
Thomas Jefferson University Hospital - 1971
Fellowship
Thomas Jefferson University Hospital - 1970
Most Recent Peer-Reviewed Publications
- Unique Geospatial Accumulations of Uveal Melanoma
- Insights from immuno-oncology: The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
- An outcome assessment of a single institution’s longitudinal experience with uveal melanoma patients with liver metastasis
- Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls
- PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma
Board Certification
Medical Oncology
Internal Medicine
Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital
Research & Clinical Interests
Dr. Mastrangelo is internationally recognized for his work in melanoma, and limits his practice to advanced cutaneous malignancies, especially cutaneous melanoma. In addition to collaborating with Dr. David Berd in the development of the autologous melanoma vaccine, Dr. Mastrangelo has also worked to explore the use of topical/intralesional wild-type and recombinant (GM-CSF) vaccinia viruses in the treatment of malignant melanoma and bladder cancer. His professional objectives are to improve the clinical outcome for patients with cutaneous melanoma through a better understanding of the biology of the disease, especially as it relates to tumor-host interactions. His clinical research has focused on intralesional therapy with microbial products, especially recombinant oncolytic viruses.